Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)

Phase 4TerminatedNCT00120380

Hannover Medical School40 enrolled

Overview

The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist bosentan.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension

Interventions

Aerosolized iloprostDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * IPAH * \> 3 months treatment with bosentan * 6 minute walk distance 150 - 425 m Exclusion Criteria: * other forms of pulmonary hypertension * severe comorbidities * cotreatment with sildenafil or investigational drugs

Locations (1)

Hannover Medical School

Hanover, Germany

Outcomes

Primary Outcomes

6 minute walk test

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.